Blood Pressure in Treated Hypertensive Individuals With the MTHFR 677TT Genotype Is Responsive to Intervention With Riboflavin: Findings of a Targeted Randomized Trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Intervention with riboflavin was recently shown to produce genotype-specific lowering of blood pressure (BP) in patients with premature cardiovascular disease homozygous for the 677C→T polymorphism (TT genotype) in the gene encoding the enzyme methylenetetrahydrofolate reductase (MTHFR). Whether this effect is confined to patients with high-risk cardiovascular disease is unknown. The aim of this randomized trial, therefore, was to investigate the responsiveness of BP to riboflavin supplementation in hypertensive individuals with the TT genotype but without overt cardiovascular disease. From an available sample of 1427 patients with hypertension, we identified 157 with the MTHFR 677TT genotype, 91 of whom agreed to participate in the trial. Participants were stratified by systolic BP and randomized to receive placebo or riboflavin (1.6 mg/d) for 16 weeks. At baseline, despite being prescribed multiple classes of antihypertensive drugs, >60% of participants with this genotype had failed to reach goal BP (≤140/90 mm Hg). A significant improvement in the biomarker status of riboflavin was observed in response to intervention (P<0.001). Correspondingly, an overall treatment effect of 5.6±2.6 mm Hg (P=0.033) in systolic BP was observed, with pre- and postintervention values of 141.8±2.9 and 137.1±3.0 mm Hg (treatment group) and 143.5±3.0 and 144.3±3.1 mm Hg (placebo group), whereas the treatment effect in diastolic BP was not significant (P=0.291). In conclusion, these results show that riboflavin supplementation targeted at hypertensive individuals with the MTHFR 677TT genotype can decrease BP more effectively than treatment with current antihypertensive drugs only and indicate the potential for a personalized approach to the management of hypertension in this genetically at-risk group. Clinical Trial Registration—: URL:http://www.clinicaltrials.gov. Unique identifier: ISRCTN23620802.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004
Ong, K. L., Cheung, B. M. Y., Man, Y. B., Lau, C. P., & Lam, K. S. L. (2007) · Hypertension · doi:10.1161/01.hyp.0000252676.46043.18 · Cited by 1,395
Genome-wide association study of blood pressure and hypertension
Levy, D., Ehret, G. B., Rice, K., Verwoert, G. C., Launer, L. J., Dehghan, A., Glazer, N. L., Morrison, A. C., Johnson, A. D., Aspelund, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.384 · Cited by 1,364 · cited 1×
“Recent genome-wide association studies in >150 000 individuals have identified several genetic loci associated with BP variation.(9,10) One study identified an association between BP and common variants in 8 genetic loci, including one near the gene encoding the folate-metabolizing enzyme methylenetetrahydrofolate red…”
BackgroundGenome-wide association study identifies eight loci associated with blood pressure
Wellcome Trust Case Control Consortium, Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., Najjar, S. S., Zhao, J. H., Heath, S. C., et al. (2009) · Nature Genetics · doi:10.1038/ng.361 · Cited by 1,215
Antoniades, C., Shirodaria, C., Warrick, N., Cai, S., de Bono, J., Lee, J., Leeson, P., Neubauer, S., Ratnatunga, C., Pillai, R., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.612325 · Cited by 365
(1977) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1977.03270300059008 · Cited by 334
Cited by
Biomarkers of Nutrition for Development—Folate Review
Bailey, L. B., Stover, P. J., McNulty, H., Fenech, M. F., Gregory, J. F., Mills, J. L., Pfeiffer, C. M., Fazili, Z., Zhang, M., Ueland, P. M., et al. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206599 · Cited by 1,136
Self-citationBerger, M. M., Shenkin, A., Schweinlin, A., Amrein, K., Augsburger, M., Biesalski, H.-K., Bischoff, S. C., Casaer, M. P., Gundogan, K., Lepp, H.-L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.02.015 · Cited by 615
Zwart, S. R., Gibson, C. R., Gregory, J. F., Mader, T. H., Stover, P. J., Zeisel, S. H., & Smith, S. M. (2017) · The FASEB Journal · doi:10.1096/fj.201700294 · Cited by 59
“Riboflavin supplementation has been shown to reduce blood pressure inhypertensivepatientswith theminor formof the MTHFR 677 polymorphism (TT), and may play a role in preventing endothelial dysfunction (97, 98).”
BackgroundAljaadi, A. M., How, R. E., Loh, S. P., Hunt, S. E., Karakochuk, C. D., Barr, S. I., McAnena, L., Ward, M., McNulty, H., Khor, G. L., et al. (2019) · The Journal of Nutrition · doi:10.1093/jn/nxz151 · Cited by 31
Self-citation
Metadata
- Authors
- Wilson, C. P., McNulty, H., Ward, M., Strain, J. J., Trouton, T. G., Hoeft, B. A., Weber, P., Roos, F. F., Horigan, G., McAnena, L., & Scott, J. M.
- Venue
- Hypertension
- Published
- 2013-06
- Volume
- 61
- Issue
- 6
- Pages
- 1302-1308
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2097992938
- Cited by
- 98
- References
- 8
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood Pressure in Treated Hypertensive Individuals With the MTHFR 677TT Genotype Is Responsive to Intervention With Riboflavin: Findings of a Targeted Randomized Trial. https://app.cochat.ai/papers/10.1161/hypertensionaha.111.01047
- The paper
- Wilson, C. P., McNulty, H., Ward, M., Strain, J. J., Trouton, T. G., Hoeft, B. A., Weber, P., Roos, F. F., Horigan, G., McAnena, L., & Scott, J. M. (2013). Blood Pressure in Treated Hypertensive Individuals With the MTHFR 677TT Genotype Is Responsive to Intervention With Riboflavin: Findings of a Targeted Randomized Trial. Hypertension. https://doi.org/10.1161/hypertensionaha.111.01047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.